Adjunctive biomarkers for improving diagnosis of tuberculosis and monitoring therapeutic effects

Yun Gyoung Hur, Young Ae Kang, Sun Hee Jang, Ji Young Hong, Ahreum Kim, Sang A. Lee, Youngmi Kim, Sang Nae Cho

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Objectives: To identify host biomarkers associated with latent tuberculosis infection (LTBI), active tuberculosis (TB), and nontuberculous mycobacteria (NTM) diseases to improve diagnosis and effective anti-TB treatment. Methods: Active TB and NTM patients at diagnosis, recent TB contacts, and normal healthy subjects were recruited. Tuberculin skin tests, QuantiFERON-TB Gold In-Tube tests, and multiplex bead arrays with 17 analytes were performed. TB patients were re-evaluated after 2 and 6 months of treatment. Results: Mycobacterium tuberculosis (M. tb) antigen-specific IFN-γ, IL-2, and CXCL10 responses were significantly higher in active TB and LTBI compared with controls (P<0.01). Only serum VEGF levels varied between the active TB and LTBI groups (AUC=0.7576, P<0.001). Active TB and NTM diseases were differentiated by serum IL-2, IL-9, IL-13, IL-17, TNF-α and sCD40L levels (P<0.05). Increased sCD40L and decreased M. tb antigen-specific IFN-γ levels correlated with sputum clearance of M. tb after 2 months of treatment (P<0.001). Conclusions: Serum IL-2, IL-9, IL-13, IL-17, TNF-α, sCD40L and VEGF-A levels may be adjunctive biomarkers for differential diagnosis of active TB, LTBI, and NTM disease. Assessment of serum sCD40L and M. tb antigen-specific IFN-γ, TNF-α, and IL-2 levels could help predict successful anti-TB treatment in conjunction with M. tb clearance.

Original languageEnglish
Pages (from-to)346-355
Number of pages10
JournalJournal of Infection
Volume70
Issue number4
DOIs
Publication statusPublished - 2015 Apr 1

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Adjunctive biomarkers for improving diagnosis of tuberculosis and monitoring therapeutic effects'. Together they form a unique fingerprint.

  • Cite this